Shaping a new era of global health investment, policy, planning and prevention
AVAC Meeting in NYC
Advocacy and activism have been a linchpin in the history of HIV treatment and prevention. The visionary work of passionate advocates has resulted in hard-fought global gains against HIV.
AVAC is part of a robust civil society movement helping to shape a new era of global health spending and planning related to HIV prevention. We mobilize to ensure programs, products and policies are evidence-based, inclusive and effective. With our partner network, we identify critical needs and develop strategic campaigns to advance HIV prevention, with a focus on ensuring a rich pipeline of options move through research and development, and rollout effectively to reach the communities who need them most.
Our advocacy takes place:
Where funders, policies and programs come together.
At the point of service delivery, where options from the pipeline must become choices in people’s lives.
At Parliaments, State Houses, Ministries of Health, National legislatures, and international bodies,to press for global and country accountability.
In the hands of robust and sophisticated coalitions of African-led civil society organizations.
The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation.
On February 10, AVAC led other organizations to sue the US government including the President, the US State Department and USAID, seeking emergency relief from an Executive Order that inhumanely froze all funding for foreign assistance. This case may well help to determine the future of foreign assistance, executive overreach, and the role of evidence, facts, and values in US policy.
AVAC’s Executive Director, Mitchell Warren and Public Citizen Litigator, Lauren Bateman explain these lawsuits and why they matter.
WHO and partners, including AVAC, will convene to to launch the Lancet Global health series: Shaping the Future of Clinical Trials. More details to come.
AVAC Senior Program Manager for Policy, John Meade Jr., describes PEPFAR’s historic legacy and strongly argues for its continued importance in the face of attacks by the new US administration. This piece appears in The Broadsheet, the magazine published by the Congressional Black Caucus Health Braintrust.
